BeOne signs $2B deal for option on preclinical trispecific antibody from China’s Huahui Read more →
GSK’s $700M Alector bet blows up as Alzheimer’s drug flunks phase 2 Read more →
Avalyn heads to Nasdaq with oversized $300M IPO to fund reformulated respiratory drugs Read more →
